Navigation Links
January 1 Looms Large for Lymphoma Patients
Date:11/27/2007

Action necessary before year end to prevent loss of access to crucial

lymphoma drugs

WHITE PLAINS, Nov. 27 /PRNewswire/ -- The Leukemia & Lymphoma Society is urging the U.S. Department of Health and Human Services (HHS) to reverse detrimental changes to reimbursement rates for two lymphoma drugs. If the HHS does not act, the changes would severely limit the availability of the two therapies, which for thousands of non-Hodgkin lymphoma (NHL) patients represent their best or only resort for effective treatment.

The Centers for Medicare and Medicaid Services (CMS), an HHS division, has set reimbursement levels for these drugs, effective Jan. 1, which will create unreasonable obstacles to accessing these lifesaving therapies.

The drugs in jeopardy are two radioimmunotherapies -- Bexxar(R) and Zevalin(R) -- which are both critically important treatment options for patients with NHL. The drugs work by delivering a radioactive isotope to the cancer cells. CMS has established reimbursement levels for the 2008 hospital outpatient prospective payment system, which will result in less than 50 percent coverage for Bexxar and Zevalin. Hospitals will not be able to cover the other half of these costly drugs, thereby effectively eliminating access to these treatments.

The Society urges the following steps be taken immediately:

-- CMS should classify the radioimmunotherapy regimen a specified covered

patient drug. The Society believes that the CMS improperly considers

the initial doses of radioimmunotherapies to be diagnostic rather than

therapeutic doses. This is not consistent with U.S. Food and Drug

Administration labeling or with current practice.

-- CMS should cover the cost of compounding radioimmunotherapies.

Institutions should be paid fairly for the costs associated with

compounding these products.

-- The agency should consider setting payment for radioimmunotherapies on

the basis of 106 percent of average sales price or a composite

ambulatory payment classification that would reflect the entire costs

of the radioimmunotherapy regimen.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society, headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The Society's mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, the Society has invested more than $550 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, the Society made 5.1 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit http://www.LLS.org or call the Society's Information Resource Center (IRC), a call center staffed by master's level social workers, nurses and health educators who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

Contact: Andrea Greif

914.821-8958

andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008.
2. Wyeth Announces Election of Bernard Poussot as CEO of Company Effective January 1, 2008
3. National Association of Subrogation Professionals (NASP), the Largest Insurance Subrogation Association in the World - Announced Today that Leslie Wiernik has Joined the Organization as Director of Education
4. Work time is the largest influence to the duration of a persons sleep
5. Large intensive care study reveals vital recommendations for treatment of brain injury patients
6. One of the Largest Post-WHI Physician Surveys Shows More Education is Needed: Patient Misinformation About Hormone Therapy Remains High
7. Texas Largest Physician Carrier Announces 5th Successive Rate Cut on Anniversary of Lawsuit Reform
8. Preventing or reducing enlarged heart decreases risk of heart failure
9. A Place for Mom, Nations Largest Senior Care Referral Service, Fills a Gap in Employee Benefits
10. AHRQ and FDA to Collaborate in Largest Study Ever of Possible Heart Risks with ADHD Medications
11. Worlds Largest Exhibit of Princess Dianas Dresses Hosted by Appleton Museum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
Breaking Medicine Technology: